61·
2 days agoJammers for personal use is going to get so hot
- 0 Posts
- 234 Comments
Joined 2 years ago
Cake day: May 20th, 2024
You are not logged in. If you use a Fediverse account that is able to follow users, you can follow this user.
28·2 days agoLol no, cops are definitely part of the problem. This reaction over fake plates is not sane
For anyone that hate microslop more than themself and enjoy pain i will provide this to aide in making your own pki, with blackjack and hookers:
https://www.rodsbooks.com/efi-bootloaders/controlling-sb.html#creatingkeys
You can get a not too old xperia 5 or 10 from ali for a pretty decent price, probably an x3 compact for a much lower price as well
Kde connect really is amazing, its on all my devices
Or you could just change to an os that doesnt piss on its users constantly
171·5 days agoDont be too hard on them, theyre just a corporate user
Sure, but what if youve configured your waf or w/e incorrectly, what if someone gains access to another part of your network? Having sane firewall settings is always better than none at all.
Prison in Greenland is pretty nice, even better than Norwegian prison.
Lets just deport them or lease cells in another prison, like north korea
Hopefully elol gets the point that he cant take up unlimited place in space for his 5g radars, sharing is caring
Dbus introduced the concept, sure, but it doesnt break your entire system for resetting it, systemd does
Will someone just end the yapping of that geriatric pedo pretty please
Lol, Microsoft will never give up on telemetry and spying
31·14 days agoIt is going to make fingerprinting more annoying while evading default port scans. That isnt nothing but you do you boo
43·15 days agoAh yes, Americans, the epitome of health. One could never guess that you dont drink fluoride, amazing.
Drink more water
C.R.C. has received research support from the American Foundation for Suicide Prevention, Assurex Health, August Busch IV Foundation, Barnes-Jewish Hospital Foundation, LivaNova, National Institute of Mental Health, and the Taylor Family Institute for Innovative Psychiatric Research. He has also consulted for LivaNova. A.J.R. has received consulting fees from Beckley Psytech Inc., Better Up, Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk Technologies, Inc., ICON, PLC, Johnson & Johnson (Janssen), LivaNova, MindStreet, Inc., Neurocrine Biosciences Inc., and Otsuka-US; speaking fees from LivaNova and Johnson & Johnson (Janssen); and royalties from Wolters Kluwer Health, Guilford Press, and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptomatology and its derivatives). He is also named co-inventor on 2 patents: US Patent No. 7795033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, and Wilson AS; and US Patent No. 7906283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, and Paddock S. S.T.A. is a consultant to Genomind, Janssen, LivaNova, Neuronetics, and Sage Therapeutics and has received research support from Compass Pathways and Neuronetics. M.T.B. is a former employee of and current consultant for LivaNova. C.G. is an employee of LivaNova and holds LivaNova stock. M.S.G. has received research support from Abbott, LivaNova, Neurolief, and Magnus Medical. He consults for Abbott, Hospital Corp of America, the Jacob Zabara Family Foundation, Neurolief, and Sooma. P.R.-P. is a consultant for LivaNova, Janssen Pharmaceuticals, Motif Neurotech, and Abbott Neuromodulation. R.M.A. has received research support from LivaNova, Compass Pathways, MindMed, Transcend Therapeutics, Wave Neuroscience, Magnus Medical, Janssen, Kernel, Usona Institute, and Alto Neuroscience. She has served on the advisory board for LivaNova and consulted for Starfish Neuroscience. Z.N. is a consultant to LivaNova, Magnus Medical, and Motif and has also received research support from LivaNova. C.L.K. has no conflicts to disclose. J.Z. receives research support from Boehringer Ingelheim, Compass Pathways, Hoffman-LaRoche, Johnson & Johnson (Janssen), LivaNova, Otsuka, Neurocrine Bioscience, and Sage Therapeutics and has received consulting fees from Alfasigma USA and Johnson & Johnson (Janssen). D.L.D. receives payment for clinical services for a former research patient from LivaNova, is a speaker for Janssen (esketamine nasal spray), and conducts forensic consultations, independent medical evaluations, and legal testimony for various firms. J.Q. has clinical research support from LivaNova, Neumora Therapeutics, and Johnson and Johnson; has been a consultant for LivaNova; and receives copyrights from Artmed Editora, Artmed Panamericana, and Elsevier/Academic Press. Y.S. has no conflicts of interest to declare. W.D. has received research support from Abbott Nutrition, AbbVie, Acadia, Akili, Alkermes, Allergan, Alto Neuroscience, AriBio, Axsome, Biohaven, Bionomics, Clexio, Compass Pathways, Corcept, Corium, Denovo Biopharma, Emalex, GlaxoSmithKline Biologicals, Hoffmann-LaRoche, Intra-Cellular, Ironshore, Janssen, Jazz, LivaNova, Lumos, Merck Sharp & Dohme, Neurocrine Biosciences, NRx, Otsuka, Sage Therapeutics, Sanofi Pasteur, Shire, Sirtsei, Spark Neuro, Sumitomo, Sunovion, and Supernus. He is on a speakers bureau or advisory board or is a consultant for Abbott Neuromodulation, Corium, and LivaNova. B.J.M. received research support from NIH, NSF, Wellcome Leap, PCORI, Health Rhythms, LivaNova, Compass, and Abbott and consulting fees from Inside Edge, VML, Atheneum, Guidepoint, Kx Advisors, and S2N Health. M.S. states the following disclosures: LivaNova, Compass Pathfinder Limited, Neurocrine Biosciences, Neumora Therapeutics, Lilly, and Eisai. G.A. receives research support from AbbVie, Accera, Axsome, Axovant, Biogen, Eisai, Eli Lily, Neurotrope, Genentech, Intra-Cellular, Janssen, Lundbeck, Neurim, Novartis, Otsuka, Roche, Sage, Suven, and TransTech and is on the speakers bureau of and a consultant for AbbVie, Acadia, Alkermes, Axsome, Biogen, Janssen, Idorsia, Lundbeck, Myriad, Neurocrine, Nestle, Otsuka, Sage, Sunovion, Teva, and Takeda. L.M. has received research funding administered through Stony Brook University from Janssen Pharmaceuticals (developer of esketamine) to conduct clinical trials with esketamine, received research funding administered through Stony Brook University from LivaNova (the developer of vagus nerve stimulation [VNS] technology) to conduct clinical trials with VNS, and served as a consultant and member of the Spravato speakers bureau for Janssen Pharmaceuticals. Q.T. is an employee of LivaNova. C.F.Z. served on the Scientific Advisory Board of Sage Therapeutics and had equity in the company. He has received royalties from Oxford University Press and research support from the Taylor Family Institute for Innovative Psychiatric Research and the Bantly Foundation. M.M. discloses the following over the last 24 months: (1) Received research support from Alto, Boehringer Ingelheim, LivaNova, Janssen, Merck, Neurocrine, Otsuka, SAGE, PCORI, and NIH/NIMH. All clinical trial payments were made to the University of Alabama at Birmingham. (2) Served as a paid consultant for the CME Institute, NuSachi Labs, PharmaTher, Residents Medical, Tactical Mind Solutions, and the University of Missouri. (3) Received royalties from Springer Nature for textbooks published. M.B. has the following disclosures to declare: AbbVie, Intra-Cellular, Axsome, Janssen, and Teva. He is also a consultant for LivaNova. C.C. has received research support for conducting clinical trials from AFSP, Clexio, ATAI, and Janssen and consulting fees from Compass Therapeutics and Boehringer. J.I.B. receives research support from Teva Pharmaceutical Industries Ltd, Intra-Cellular Therapeutics, J&J Innovative Medicine, and Relmada Therapeutics for clinical trials, administered through the Southern Illinois University School of Medicine. He has received research support from Janssen Research and Development to conduct clinical trials with esketamine, which are also administered through the Southern Illinois University School of Medicine. H.B. has no conflicts to disclose. J.W. is a former employee of LivaNova and holds LivaNova stock. O.S. is an employee of LivaNova and holds LivaNova stock. Y.-C.(L.)L. is an employee of LivaNova and holds LivaNova stock. R.H.M.-W. reports acting as TSC chair for the NIHR HTA-funded SNAPPER trial and DMC chair for the EU-funded PReDicT study. He is Director of Education for the British Association for Psychopharmacology, receives support for meetings via Janssen-Cilag, and receives payments/consultation fees from LivaNova, Janssen-Cilag, Sage Therapeutics, P1Vital, Takeda, and Lundbeck. R.S.M. has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, NeuraWell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, and Atai Life Sciences. H.A.S. serves as a scientific advisor and receives consulting fees from Cerebral Therapeutics, Holmusk Technologies, LivaNova, MECTA Corporation, NeuroInsights, Neurolief, Neuronetics, Parow Entheobiosciences, and SigmaStim; receives honoraria and royalties from Elsevier and Oxford University Press; is the inventor of nonremunerative US patents for focal electrically administered seizure therapy, titration in the current domain in electroconvulsive therapy (ECT), and the adjustment of current in ECT devices, each held by the SigmaStim Corporation; and is also the originator of magnetic seizure therapy.
The statistical analyses that are reported in the article will be shared upon reasonable request to the corresponding author. The raw data are not publicly available.
Name 3